Trial Profile
A Phase IIb prospective, randomized, double-blind, placebo controlled study of NTx-265: human chorionic gonadotropin (hCG) and epoetin alfa (EPO) in acute ischaemic stroke patients (REGENESIS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*